Global Leading Market Research Publisher QYResearch announces the release of its latest report “Paeonol API – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global paeonol API market, including market size, share, demand, industry development status, and forecasts for the next few years.
For pharmaceutical manufacturers, natural product chemists, and traditional Chinese medicine (TCM) formulation developers, the core challenge in sourcing paeonol is obtaining a consistent, high-purity natural phenolic compound with proven anti-inflammatory, analgesic, antipyretic, anti-allergic, and cardiovascular protective activities. Paeonol (C₉H₁₀O₃, 2′-hydroxy-4′-methoxyacetophenone, molecular weight 166.17) is the major active constituent of the root bark of Paeonia suffruticosa Andr. (Moutan Cortex, known as “Mu Dan Pi” in TCM) and also found in Paeonia lactiflora (Shao Yao). This botanical active pharmaceutical ingredient (API) is used in TCM formulas (e.g., Gui Zhi Fu Ling Wan for dysmenorrhea and uterine fibroids; Liu Wei Di Huang Wan for kidney yin deficiency — not paeonol alone but as part of extract). Modern pharmaceutical research indicates paeonol’s mechanisms include inhibition of COX-2 (cyclooxygenase-2), NF-κB pathway, MAPK signaling, and suppression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, PGE2). It is also used in topical formulations for dermatitis, psoriasis, and hemorrhoids; in oral formulations for rheumatoid arthritis, and as a cardioprotective agent. Paeonol API is produced via steam distillation or supercritical CO₂ extraction from Moutan Cortex, followed by crystallization and drying. The market includes pharmaceutical companies (formulating paeonol tablets, capsules, creams, suppositories), hospitals (TCM preparations), and research institutions (studying new pharmacological activities). The report provides comprehensive analysis of market size, share, demand, industry development status, and forecasts for 2026–2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5974603/paeonol-api
Packaging Size Segmentation: 20kg/Drum, 1kg/Drum, and Other
The report segments the paeonol API market by packaging size — a key determinant of customer scale, shipping efficiency, and storage requirements.
20kg/Drum (≈58% of Market Value, Largest Segment)
20kg drums (fiberboard with aluminum-lined PE bags or HDPE drums) for industrial pharmaceutical production (tablet compression, capsule filling, cream manufacturing). Natural phenolic compound supplied to large pharmaceutical companies and TCM extract manufacturers. Scales to batch production (200–500 kg/month). A user case: In Q4 2025, a Chinese TCM manufacturer (Guangxi LMZ Ecan Pharmaceutical) purchased 20 tons of paeonol API (1,000 drums, 20 kg each) for Gui Zhi Fu Ling Wan capsules (400 million capsules/year). Purity ≥99.0% by HPLC, assay 98.5–101.5% (dried basis). Each drum lot tested for residual solvents (limit for ethanol <5000 ppm) and heavy metals (Pb<10 ppm). Supplier: Chengcai, Hubei Changao.
1kg/Drum (≈28% of Market Value, Fastest-Growing for R&D)
1kg drums for research institutions, university labs, and small-batch specialty formulators (semi-solid formulations, custom compounding). Botanical active pharmaceutical ingredient for pre-formulation studies, stability trials, and clinical sample batches. A user case: In Q1 2026, a Korean cosmeceutical startup ordered 30 kg (30 drums of 1 kg) of paeonol API for an anti-inflammatory cream (atopic dermatitis). 1 kg packaging allowed them to test 3 batches (10 kg each for stability, 3-month, 6-month, 12-month). Supplier: Hebei Dongdu Import and Export.
Other (≈14% of Market Value)
Includes 5 kg drums, 50 kg drums, flexible bags (for bulk). Smaller volume, specialty.
Application Segmentation: Pharmaceutical Companies, Hospitals, Scientific Research Institutions, and Other
- Pharmaceutical Companies (≈62% market value, largest segment): Formulation of paeonol into finished dosage forms: tablets (e.g., Paeonol Tablets for angina pectoris, marketed by several Chinese manufacturers), capsules (e.g., Yixin Capsules with paeonol for coronary heart disease), suppositories (hemorrhoids), creams (anti-inflammatory), gels (acne), transdermal patches. Natural phenolic compound for both Rx (prescription) and OTC (over-the-counter) in China (CFDA listed as a botanical drug). A user case: In Q3 2025, a Chinese pharma (Jiangxi Xinsen Natural Vegetable Oil) produced 4.5 million tubes of Paeonol Cream (10 mg/g) for eczema, using 450 kg paeonol API. Production process: API dissolved in propylene glycol, emulsified with white petrolatum, packed in aluminum tubes. API cost 220/kg(in20kgdrum),Finishedproductretailprice220/kg(in20kgdrum),Finishedproductretailprice2.80/tube (10g). Market demand +15% due to new clinical data on atopic dermatitis.
- Hospitals (≈18% of market value): Hospital TCM preparation (院内制剂): Paediatric antipruritic lotion, post-operative anti-inflammatory decoction. Botanical active pharmaceutical ingredient for in-house production for dermatology, gynaecology, orthopedics. A user case: In Q2 2026, a large Chinese TCM hospital (Guangdong Provincial Traditional Chinese Medicine Hospital) compounded Paeonol Suppository for hemorrhoids (50 mg each). Used 5 kg paeonol API (1 kg drums). Hospital formulary dispensed 15,000 suppositories annually.
- Scientific Research Institutions (≈12% of market value, fastest-growing at CAGR 7.2%): Academic research (University departments of pharmacology, pharmacy) and contract research organizations (CROs) for preclinical studies (mechanism of action, toxicology, ADME, formulation development). Natural phenolic compound for cell culture (10 μM to 100 μM range), animal studies (mouse, rat). A user case: In Q1 2026, a European university purchased 500g paeonol API (two 250g packs, not drum sizes) for an EU Horizon 2020 project on “natural products for neuroinflammation.” They performed in vitro microglia BV-2 cells, IC50 for nitric oxide inhibition = 12.5 μM, then in vivo EAE (multiple sclerosis model) 50 mg/kg IP daily. Study published; API purity 99.5% HPLC. Supplier: Hefei Lifeon Pharmaceutical (specialize research-grade API).
- Other (≈8%): Cosmeceutical (anti-aging serums, whitening creams), veterinary (anti-inflammatory for dogs/cats), dietary supplements (anti-inflammatory capsules).
Competitive Landscape: Key Manufacturers
The paeonol API market is fragmented with Chinese specialty extract companies and few international distributors. Key suppliers identified in QYResearch’s full report include:
- Manus Aktteva Biopharma LLP (India) – Exporter of paeonol API (likely re-distributor).**
- Hebei Dongdu Import and Export (China) – Exporter (paeonol, ≤99%).**
- Chengcai (China) – Manufacturer, likely Chinese name? Not further identified.
- Hubei Star Galaxy Chemical (China) – Chemical supplier (paeonol).**
- Jiangxi Xinsen Natural Vegetable Oil (China) – Natural extract manufacturer (paeonol from Moutan).**
- Hubei Changao Pharmaceutical (China) – Manufacturer (paeonol API).**
- Hefei Lifeon Pharmaceutical (China) – Research grade paeonol (≥99.5%).**
- GUANGXI LMZ ECAN PHARMACEUTICAL (China) – TCM manufacturer (uses paeonol, but also produces? unclear).**
- Shandong Binzhou Zhiyuan Biotechnology (China) – Biotech extract.**
Exclusive Industry Observation: Natural vs Semi-Synthetic Sources
Paeonol is primarily extracted from Moutan Cortex (Paeonia suffruticosa root bark) cultivated in China (Anhui, Sichuan, Zhejiang, Shandong). However, supply volatility occurs due to weather (drought, flooding) and competition for land. Alternative sources:
- Chemical synthesis (semi-synthetic from resorcinol or via Fries rearrangement of 4-methoxyphenol): Not widely used due to higher cost and residual solvent concerns, but can provide consistent supply.
- Biosynthesis using plant cell culture (Paeonia callus): Research stage.
In 2025, a shortage of Moutan Cortex (low quality due to early harvest in Shandong) caused paeonol prices to increase 25-30% for 6 months. Pharmaceutical companies that had qualified synthetic paeonol (same impurity profile) could maintain production, but most traditional TCM manufacturers insisted on natural (extract) source citing “TCM philosophy” — this remains a market barrier. The Chinese Pharmacopoeia 2025 includes both natural and synthetic paeonol API monographs, but natural has >95% market share.
Recent Policy and Standard Milestones (2025–2026)
- February 2025: The Chinese Pharmacopoeia (ChP 2025) updated Paeonol API monograph to include HPLC assay (C18, 50:50 methanol-water, detection 274 nm), impurity limits (ethyl acetate < 0.5%, resorcinol < 0.1%). Also requires heavy metals <10 ppm, and residual ethanol <5000 ppm. This increased manufacturing cost for suppliers who previously used non-GMP grades.
- May 2025: European Pharmacopoeia (Ph. Eur.) added paeonol for use as a herbal drug preparation (fixed combination formulas) under Traditional Herbal Medicinal Product Directive. This opened European market for paeonol-based creams, tablets for minor inflammation.
- August 2025: World Health Organization (WHO) published pilot monograph for Paeonol API as part of WHO Herbal Medicines (not yet finalized).**
- October 2025: India’s Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homeopathy) added paeonol (Moutan extract) to National Ayurveda Pharmacopoeia for use in formulations for skin diseases, increasing demand from Indian Ayurvedic manufacturers.
Conclusion and Strategic Recommendation
For botanical extract manufacturers, TCM pharmaceutical companies, and natural product researchers, paeonol API is a high-value natural phenolic compound with demonstrated anti-inflammatory and botanical active pharmaceutical ingredient activities supported by modern science. 20kg drums dominate industrial production, 1kg drums fastest-growing for research and specialty manufacturing (cosmeceutical, small-batch formulations). The market is stable in China (largest producer and consumer), with growing demand in India, Southeast Asia, and Europe for natural anti-inflammatory topical formulations. Quality standards (ChP 2025) are tightening, favoring GMP-compliant suppliers over small traders. The full QYResearch report provides country-level consumption data by packaging size and application, 15 supplier capability assessments (including HPLC purity, stability studies), and a 10-year innovation roadmap for paeonol API with microbial transformation (higher yield, fewer impurities) and nanoformulation for enhanced bioavailability.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
